Table 5.
Multivariate risk factor analysis for virologic failure at 24 and 72 weeks of antiretroviral therapy.
| Characteristics | Virologic Failure at 24 Weeks of ART | Virologic Failure at 72 Weeks of ART | ||
|---|---|---|---|---|
| aOR (95% CI) | P value | aOR (95% CI) | P value | |
| Males | 1.07 (0.96 - 1.19) | 0.25 | 1.18 (1.03 - 1.36) | 0.02 |
| Age, one-year increment | 1 (0.99 - 1) | 0.50 | 0.99 (0.99 - 1) | 0.08 |
| WHO disease stage (3 or 4 versus 1 or 2) | 1.74 (1.59 - 1.9) | <0.001 | 1.11 (0.98 - 1.24) | 0.09 |
| CD4 cell count, cells/mm3 (≤100 versus >100) | 1.27 (1.16 -1.38) | <0.001 | 1.37 (1.23 - 1.53) | <0.001 |
| Viral load (>10,000 versus ≤10,000) | 1.42 (1.28 -1.56) | <0.001 | 1.09 (0.97 - 1.24) | 0.16 |
| NVP versus EFV | 1.12 (0.99 -1.28) | 0.07 | 1.39 (1.17 - 1.65) | <0.001 |
| ABC versus TDF | 1.2 (0.93 - 1.54) | 0.16 | 0.79 (0.57 - 1.11) | 0.17 |
| AZT versus TDF | 0.78 (0.71- 0.85) | <0.001 | 0.77 (0.68 - 0.87) | <0.001 |
| D4t versus TDF | 0.66 (0.55- 0.79) | <0.001 | 0.88 (0.7 - 1.11) | 0.28 |
| ddi versus TDF | 1.08 (0.83- 1.41) | 0.56 | 1.22 (0.87 - 1.71) | 0.26 |
| Year of ART initiation | ||||
| 2007-2009 versus 2004-2006 | 0.91 (0.8 - 1.01) | 0.07 | 1.25 (1.1 - 1.42) | <0.001 |
| 2010-2012 versus 2004-2006 | 0.52 (0.45- 0.61) | <0.001 | 1.93 (1.51 - 2.46) | <0.001 |
| Adherence (<95% versus ≥95%)* |
1.82 (1.63- 2.04) | <0.001 | 1.74 (1.47 - 2.06) | <0.001 |
| Anaemia | 1.34 (1 - 1.8) | 0.048 | 1.76 (1.22 - 2.55) | <0.001 |
| lipodystrophy | 0.81 (0.6 - 1.1) | 0.18 | 0.85 (0.61 - 1.18) | 0.33 |
| CNS disturbance | - | 1.19 (0.68 - 2.05) | 0.54 | |
| peripheral neuropathy | - | 0.42 (0.18 - 1.02) | 0.06 | |
*average adherence at 24, and 72 weeks were included in the analysis of virologic outcome at 24, and 72 weeks respectively. Values in italics show a significant association.